This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by White, S. C. Articles by Ranson, M. Search for Related Content PubMed PubMed Citation Articles by White, S. C. Articles by Ranson, M.

Phase II Study of Oral Topotecan in Advanced Non-Small Cell Lung Cancer

Department of Medical Oncology, Christie Hospital National Health Service Trust, Manchester [S. C. W., S. C., N. T., H. A., B. C., M. R.], and SmithKline Beecham, Harlow [S. H., G. R.], United Kingdom

This study was designed to assess the activity of oral topotecan (TPT) in patients with advanced non-small cell lung cancer previously untreated with chemotherapy. Eligible patients had inoperable stage III or stage IV non-small cell lung cancer and were chemotherapy-naïve. Other inclusion criteria were Eastern Cooperative Oncology Group performance status 0, 1, or 2, adequate bone marrow, and renal and hepatic function. Of 30 patients, 29 were assessable for response. Oral TPT was administered for 5 days every 21 days for up to six cycles unless disease progression or unacceptable toxicity occurred. Patients received a dose of 2.3 mg/m²/day for the first cycle. Dose modification for subsequent cycles was based on tolerability. Patients completed symptom questionnaires every 3 weeks. Pharmacokinetics were evaluated in all patients during cycle 1.

Three patients had radiological responses with a reduction in tumor size of 30–40%. No patients achieved complete or partial responses to treatment. Thirteen patients had a stable disease (43.3%), and the median survival was 39.9 weeks with a 1-year survival of 33.3%. At the time of analysis, 27 patients had died. Median time to progression was 12.3 weeks.

Treatment was well tolerated. A total of 125 cycles of treatment were completed. Twelve patients (40%) experienced grade III/IV neutropenia. Five patients (16.6%) had grade III/IV anemia. There were two episodes of grade III/IV thrombocytopenia. The main nonhematological toxicities consisted of grade III nausea (13%) and grade III vomiting (13%).

The most frequently reported disease-related symptoms at baseline were dyspnea, cough, and fatigue. There was a subsequent improvement in patient scores of dyspnea in 17% of patients, 31% showed improvement in cough, and 32% showed improvement in fatigue.

The mean area under the curve of TPT following 2.3 mg/m² p.o. was 51.6 ng.h/ml (%SD, 25%). The area under the curve of TPT on day 1 of the first cycle was correlated with the percentage fall in leukocytes.

Although oral TPT at the applied dose and schedule showed modest activity as a single agent, almost one-half of the patients had a stable disease, and median time to progression was 12.3 weeks. The overall median survival was a promising 39.9 weeks, and useful palliation of symptoms was seen.

This article has been cited by other articles:

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				R. Ramlau, R. Gervais, M. Krzakowski, J. von Pawel, E. Kaukel, R. P. Abratt, B. Dharan, K. M. Grotzinger, G. Ross, G. Dane, et al. Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients With Pretreated Advanced Non-Small-Cell Lung Cancer J. Clin. Oncol., June 20, 2006; 24(18): 2800 - 2807. [Abstract] [Full Text] [PDF]

				C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]

				M. J. Guarino, C. J. Schneider, S. S. Grubbs, D. D. Biggs, A. L. Himelstein, K. Hogaboom, and S. Tilak A Dose-Escalation Study of Weekly Topotecan, Cisplatin, and Gemcitabine Front-Line Therapy in Patients with Inoperable Non-Small Cell Lung Cancer Oncologist, December 1, 2002; 7(6): 509 - 515. [Abstract] [Full Text] [PDF]